Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D
Proper PT-141 dosing protocols vary between delivery methods, with nasal formulations often requiring slightly higher doses to match injectable potency
Immunogenicity A synthetic nine-residue peptide can potentially generate an immune response, particularly when administered through an injectable route
Drink plenty of fluids and eat whole foods to prevent nausea
Another previous study demonstrated that the genetic knockout of epithelial Wls suppressed the formation of hair placode and downregulated the expression levels of BMP2, BMP4, and SHH [36]
Despite a promising in vitro antitumor activity, the development of this therapy faced off serious side effects, limiting its potential development as anticancer therapy